Untitled 3

Source R&D is the authoritative source of technology and services information supporting pharmaceutical and biotechnology companies in their drug discovery and development research projects.

Source R&D features extensive listings of service providers classified under company or organisation type, including contract chemical manufacturers; contract biologics manufacturers; biological research companies and organisations; and companies and organisations providing advisory, consultancy, legal, regulatory and other services.

The extensive coverage of Source R&D and the support of life sciences organisations One Nucleus and Bionow make it an invaluable reference tool that streamlines the vendor selection process to bring pharmaceutical/biotechnology companies and suppliers together.

Expedeon AG signs supply agreement with Reszon Diagnostics for proprietary colloidal gold technology

Expedeon logo 11.10.18Reszon Diagnostics logo 11.10.18Expedeon AG has signed a three-year supply agreement for its colloidal gold with Malaysia-based Reszon Diagnostics International Sdn. Bhd, part of Revongen Corporation and a developer and manufacturer of innovative in-vitro diagnostics (IVD) rapid test kits and of ELISA kits. Reszon’s operations cover Asia, the Middle East, sub-Saharan Africa and the USA.

Expedeon will supply Reszon with its proprietary colloidal gold, an aqueous suspension of spherical metallic nanoparticles that provide high-efficiency antibody binding for maximum sensitivity. Reszon will use the gold nanoparticles in the manufacture of its diagnostic lateral flow assays (LFAs). The company will also be testing Expedeon’s InnovaCoat® GOLD nanoparticles to increase the sensitivity of LFAs that are already on the market. InnovaCoat® GOLD nanoparticles have a proprietary surface coating that covalently binds antibodies or proteins to form highly stable conjugates. The technology is fully scalable and is subject to stringent QC testing to ensure consistent high quality and excellent batch-to-batch reproducibility.

For further information about Expedeon AG visit www.expedeon.com and for further information about Reszon Diagnostics visit www.reszonics.com

Last modified onSaturday, 13 October 2018 04:22